
IRLAB Therapeutics AB
STO:IRLAB A

Intrinsic Value
The intrinsic value of one
IRLAB A
stock under the Base Case scenario is
16.13
SEK.
Compared to the current market price of 6.95 SEK,
IRLAB Therapeutics AB
is
Undervalued by 57%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
IRLAB Therapeutics AB
Fundamental Analysis


Revenue & Expenses Breakdown
IRLAB Therapeutics AB
Balance Sheet Decomposition
IRLAB Therapeutics AB
Current Assets | 79.6m |
Cash & Short-Term Investments | 66.9m |
Receivables | 12.6m |
Non-Current Assets | 56.7m |
PP&E | 9.8m |
Intangibles | 46.9m |
Other Non-Current Assets | -1k |
Free Cash Flow Analysis
IRLAB Therapeutics AB
SEK | |
Free Cash Flow | SEK |
Earnings Waterfall
IRLAB Therapeutics AB
Revenue
|
94.6m
SEK
|
Cost of Revenue
|
-136.3m
SEK
|
Gross Profit
|
-41.7m
SEK
|
Operating Expenses
|
-33.5m
SEK
|
Operating Income
|
-75.1m
SEK
|
Other Expenses
|
-8m
SEK
|
Net Income
|
-83.1m
SEK
|
IRLAB A Profitability Score
Profitability Due Diligence
IRLAB Therapeutics AB's profitability score is 10/100. The higher the profitability score, the more profitable the company is.

Score
IRLAB Therapeutics AB's profitability score is 10/100. The higher the profitability score, the more profitable the company is.
IRLAB A Solvency Score
Solvency Due Diligence
IRLAB Therapeutics AB's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Score
IRLAB Therapeutics AB's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IRLAB A Price Targets Summary
IRLAB Therapeutics AB
Dividends
Current shareholder yield for IRLAB A is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IRLAB A
stock under the Base Case scenario is
16.13
SEK.
Compared to the current market price of 6.95 SEK,
IRLAB Therapeutics AB
is
Undervalued by 57%.